DMT Pretreatment Sequencing to Reduce Anxiety and Disorientation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid onset and intensity of inhaled DMT can be disorienting and anxiety-producing, undermining the subjective experience and reducing beneficial effects, while state-level legal changes permit supervised adult use of psychedelics, necessitating improved methods for administering DMT to enhance wellbeing and reduce anxiety.
Innovation Solution
Administering a long-acting tryptamine, such as psilacetin, prior to DMT, optionally with benzodiazepines like lorazepam and ketamine, to modulate the subjective experience, reducing side effects and enhancing positive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If inhaled DMT is administered, then rapid onset of psychedelic effects is achieved, but disorientation and anxiety are produced
Solution Approach 1:
The patent applies preliminary action by administering a long-acting tryptamine (such as psilocybin, psilocin, or 4-HO-DMT) before administering DMT. This pre-treatment prepares the subject's system in advance to modulate the subsequent DMT experience, reducing the harmful effects of rapid onset while preserving the beneficial psychedelic effects. The long-acting tryptamine remains active in the system during DMT administration, creating a buffering effect that mitigates anxiety and disorientation.
2Power
If inhaled DMT is administered, then intense psychedelic effects are achieved, but beneficial effects are reduced
Solution Approach 1:
The long-acting tryptamine is administered in advance to establish a modulating presence during the DMT experience. This preliminary preparation ensures that when intense DMT effects occur, they are buffered by the ongoing presence of the long-acting compound, which helps maintain reliability of beneficial effects while preserving intensity.
Solution Approach 2:
The long-acting tryptamine serves as an intermediary substance that mediates between the subject and the intense DMT effects. It acts as a buffer or moderator, allowing the intense psychedelic experience to occur while simultaneously reducing harmful aspects and preserving beneficial outcomes. The intermediary compound translates the raw intensity of DMT into a more reliable and beneficial experience.
3Reliability
If combination therapy with long-acting tryptamine and benzodiazepines is used, then positive effects are enhanced, but device complexity increases
Solution Approach 1:
The combination protocol uses preliminary action by administering the long-acting tryptamine first, followed by benzodiazepines at strategically timed intervals before DMT administration. This sequential pre-preparation enhances the reliability of positive effects by ensuring both compounds are at optimal levels in the system during DMT experience, despite the increased complexity of the multi-step protocol.
Data Source
AI summary
The present disclosure relates in some aspects to methods for modulating and improving the subjective experience of N,N-dimethyltryptamine (DMT) by administering DMT after a long-acting tryptamine such as psilacetin, and in some embodiments, together with a benzodiazepine and/or ketamine, or in some further embodiments, together with a second long-acting psychedelic. In some aspects, disclosed methods are useful for treating medical conditions, such as mental health disorders and neurodegenerative disorders. In some aspects, disclosed methods are useful for improving health and wellbeing, such as in healthy people.